Zobrazeno 1 - 10
of 18
pro vyhledávání: '"A. D. M. Vorselaars"'
Autor:
M. C. Schimmelpennink, D. B. Meek, A. D. M. Vorselaars, L. C. M. Langezaal, C. H. M. van Moorsel, J. J. van der Vis, M. Veltkamp, J. C. Grutters
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Advanced pulmonary sarcoidosis causes significant morbidity and can lead to death. Large trials demonstrated efficacy of antifibrotics in patients with progressive fibrosing interstitial lung diseases (PF-ILD), including a few wit
Externí odkaz:
https://doaj.org/article/c46a96ad0a0948658b14e8264ff2d4c3
Autor:
Sofia A. Moll, Mark G. J. P. Platenburg, Anouk C. M. Platteel, Adriane D. M. Vorselaars, Montse Janssen Bonàs, Raisa Kraaijvanger, Claudia Roodenburg-Benschop, Bob Meek, Coline H. M. van Moorsel, Jan C. Grutters
Publikováno v:
PLoS ONE, Vol 17, Iss 11 (2022)
Background Serologic testing for autoantibodies is recommended in interstitial lung diseases (ILDs), as connective tissue diseases (CTDs) are an important secondary cause. Myositis antibodies are associated with CTD-ILD, but clinical associations wit
Externí odkaz:
https://doaj.org/article/aa26dc504bac4744b8479c8d671dbba4
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-7 (2019)
Abstract Background 18F-FDG PET/CT has proven to be a reliable tool for therapy monitoring in sarcoidosis. Previous PET studies investigated the SUVmax as a marker for disease activity. Total lung glycolysis (TLuG) is a new tool, quantifying the glyc
Externí odkaz:
https://doaj.org/article/c46ad77df8be439c8c11a5337693fb5c
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Sarcoidosis is a heterogeneous disease in terms of presentation, duration, and severity. Due to this heterogeneity, it is difficult to align treatment decisions. Biomarkers have proved to be useful for the diagnosis and prognosis of many diseases, an
Externí odkaz:
https://doaj.org/article/d609f1b818514f82b5aa2699609e2f83
Publikováno v:
Current Opinion in Pulmonary Medicine. 28:461-467
The treatment of sarcoidosis remains uncertain, despite 70 years of study. The conventional approach is to initiate corticosteroids in individuals who require treatment. The position of more aggressive regimes is unknown.Recent recognition that many
Publikováno v:
Cells, Vol 10, Iss 2, p 441 (2021)
The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade® or Inflectra® to Flixabi® in patients with se
Externí odkaz:
https://doaj.org/article/2d23af50e2704783aebca3a68244f973
Autor:
Sofia A. Moll, Mark G. J. P. Platenburg, Anouk C. M. Platteel, Adriane D. M. Vorselaars, Montse Janssen Bonàs, Claudia Roodenburg-Benschop, Bob Meek, Coline H. M. van Moorsel, Jan C. Grutters
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 9, p 2944 (2020)
Connective tissue diseases (CTDs) are an important secondary cause of interstitial lung disease (ILD). If a CTD is suspected, clinicians are recommended to perform autoantibody testing, including for myositis autoantibodies. In this study, the preval
Externí odkaz:
https://doaj.org/article/00231f1ffecb4f5a84eef1e4ea3140f9
Publikováno v:
Case Reports in Pulmonology, Vol 2013 (2013)
Introduction. Although the role of TNF-α in tumor development is not fully understood, an increased risk of malignancy with TNF-α-inhibitors, such as infliximab, has been suggested. Case Presentation. We present a 54-year-old nonsmoking female sarc
Externí odkaz:
https://doaj.org/article/53f78cc67cef4edb8e9c8d47aa54c66a
Publikováno v:
Journal of the American Medical Informatics Association
Autor:
Milou C, Schimmelpennink, Adriane D M, Vorselaars, Frouke T, van Beek, Heleen A, Crommelin, Vera H M, Deneer, Ruth G M, Keijsers, Marcel, Veltkamp
Publikováno v:
Respiratory medicine.
Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, RemicadeIn this retrospective cohort study, 29 patients treated with the infli